First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Go Back

Share this story

Comments


Related articles


Professor Andrea Kuhn

sponsored article

Advances

“A big step forward” – introducing next generation deep brain stimulation

How Medtronic is pioneering greater personalisation in DBS therapy

READ MORE
Crowded sidewalk on Oxford Street in London

Special reports

Parkinson’s prevalence expected to increase by 18% in next seven years

Aging UK population could see increase in Parkinson’s over time

READ MORE
Heather Kennedy lead

Perspectives

World Parkinson Congress 2019 Bloggers: Heather Kennedy

#WPC2019: We talk to American blogger Heather Kennedy

READ MORE